Christian Müller, Christoph C. Zielinski – 1 November 1990 – We investigated lipopolysaccharide‐induced tumor necrosis factor production in vitro by peripheral blood monocytes from patients with various liver diseases.
V. J. Desmet, Peter van Eyken, Raf Sciot – 1 November 1990 – Immunohistochemistry with monoclonal anti‐cytokeratin antibodies has revealed the presence of cytokeratin 19 in embryonic and early fetal hepatocytes. With the differentiation of bile ducts at about the 10th week, cytokeratin 19 disappears from liver cells but remains in bile duct cells. This marks an important step in the organogenesis of the liver.
Ian R. Wanless, Powers Peterson, Asha Das, John K. Boitnott, G. William Moore, Vincent Bernier – 1 November 1990 – The pathogenesis of portal hypertension arising in patients with myeloproliferative disorders has been difficult to understand because liver biopsy findings often show minimal changes. It has been suggested that increased splenic blood flow, hepatic infiltration with hematopoietic cells or sinusoidal fibrosis may be important.
Peter Karayiannis, John Saldanha, John Monjardino, Robert Goldin, Janice Main, Shashi Luther, Mark Easton, Antonio Ponzetto, Howard C. Thomas – 1 November 1990 – To assess the role of immunization against hepatitis delta antigen in the prevention of hepatitis delta virus infection, woodchuck carriers of woodchuck hepatitis virus were immunized with a 64 amino acid portion of hepatitis delta antigen from its N‐terminal region. The protein was expressed in Escherichia coli and contained a major immunogenic epitope.
Ian R. Wanless, John S. Lentz – 1 November 1990 – Steatohepatitis (fatty liver hepatitis), histologically identical to alcoholic disease, occurs in some obese patients after jejunoileal bypass. A similar lesion occurs rarely in obese patients without bypass surgery, but the risk factors are poorly understood. Hepatic steatosis, steatohepatitis and fibrosis were sought in 351 apparently nonalcoholic patients at autopsy and various risk factors were evaluated. Incidence of steatosis and steatohepatitis correlated with the degree of obesity.
Philippe Marteau, Olivier Chazouiléres, Anne Myara, Raymond Jian, Jean‐Claude Rambaud, Raoul Poupon – 1 November 1990 – The effect of long‐term administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids was determined using the tauro 23 (75Se) selena‐25 homotaurocholic acid test in a controlled double‐blind study involving healthy subjects (n = 15). Subjects received placebo or 13 to 15 mg/kg/day ursodeoxycholic acid for 5 wk.
Ieharu Hishinuma, Jun‐Ichi Nagakawa, Kazuo Hirota, Kaname Miyamoto, Kazuo Tsukidate, Takashi Yamanaka, Kou‐Ichi Katayama, Isao Yamatsu – 1 November 1990 – Intravenous injection of lipopolysaccharide and D‐galactosamine, at doses of 0.2 μg/kg and 800 mg/kg, respectively, elicited massive hepatic necrosis within 24 hr in C3H/HeN mice. The plasma L‐alanine aminotransferase (ALT, E.C. 2.6.1.2) or L‐aspartate aminotransferase (AST, E.C. 2.6.1.1) activities at this point reached more than 2,000 IU/L.
Jiřina Martínková, Josef Bulas, Vladimír Krejčí, Miroslav Hartman, Ivan Tilšer, Petr Hůlek – 1 November 1990 – We have studied the action of a series of vasoactive and antispasmodic agents on the intrahepatic vasoconstriction induced by adrenaline in the isolated perfused liver of rabbits. The arterial and portal venous resistance, oxygen consumption, liver weight and bile flow were investigated.
Yao Zhiqiang, Yang Weisong, Zhang Wenbin, Chen Yong, Yang Fengyi – 1 November 1990 – Current support or replacement therapies for fulminant acute hepatic failure are frequently very disappointing. In this study, human hepatic stimulator substance—a liver‐specific growth factor—was partially purified from human fetal liver cells and characterized by its biological effects. Almost 70‐fold protein content was purified with an approximately 80‐fold increase in specific growth stimulator activity.
Linda J. Scully, David Brown, Chris Lloyd, Ruvan Shein, Howard C. Thomas – 1 November 1990 – Lymphoblastoid interferon is effective therapy in some but not all patients with chronic hepatitis B virus infection. To assess whether immunological parameters were predictive of response to interferon therapy, we determined the human leukocyte antigen type, CD4/CD8 ratio, natural killer cell activity, IgM anti‐HBc antibody levels and concanavalin A—induced lymphocyte proliferative response in 30 patients before treatment.